Lung Fibrosis InterstitialFILIPNCT07457463
Evaluation of the Pulmonary Fibrosis Learning and Self-management Programme (FILIP)
A study testing Blended patient education and self-management programme in people with Lung Fibrosis Interstitial, run by Insel Gruppe AG, University Hospital Bern at 2 sites in Switzerland.
Trial summary
The goal of this observational study is to evaluate the feasibility and acceptability of a newly developed digital education and self-management program for people with fibrotic interstitial lung diseases (FILD) during inpatient pulmonary rehabilitation and outpatient interstitial lung disease (ILD) care. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Fibrosis Interstitial
- What is being tested?
- Blended patient education and self-management programme
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 2 sitesSwitzerland
- Study dates
- 7 Oct 2025to Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of a FILD as major indication for pulmonary rehabilitation (for Berner Reha Zentrum only)
- Enrolled in Idiopathic interstitial Pneumonia (IIP) cohort study (Nr. 246/15 / PB_2016-01524) and agreed to further use of data for further research purpose (for Inselspital only)
- Age ≥ 18 years
- Written informed consent
Who cannot join
- Cognitive inability or insufficient knowledge of project language (German) to follow informed consent or study procedures
- Sarcoidosis
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland2 sites, 2 recruiting
- Not yet recruiting
Department for Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Bern, 3010
Sabina Guler, MD, +41 31 632 21 11, sabina.guler@insel.ch
- Recruiting
Center for Rehabilitation & Sports Medicine Inselspital and Berner Reha Zentrum, Bern University Hospital, University of Bern, Switzerland
Heiligenschwendi, 3625
Thimo Marcin, PhD, +41 33 244 3048, thimo.marcin@insel.ch
About this study
Official title: Self-efficacy and Well-being of Patients With Fibrotic Interstitial Lung Disease - an Observational Study
The goal of this observational study is to evaluate the feasibility and acceptability of a newly developed digital education and self-management program for people with fibrotic interstitial lung diseases (FILD) during inpatient pulmonary rehabilitation and outpatient interstitial lung disease (ILD) care. The study also explores whether participation in the program is associated with changes in health-related outcomes.
The main questions this study aims to answer are:
Read more
- Is the digital education and self-management program acceptable, useful, and practical for patients with FILD?
- Is it feasible to recruit and retain patients and to collect outcome data for a future larger effectiveness study?
- Do patients who participate in the program show differences in health-related outcomes compared with patients treated before the program was implemented?
Patients who consent to participate during the implementation phase will be offered access to the digital education and self-management program. Their outcomes will be compared with those of a historical cohort of patients who received usual care before the program was introduced.
Participants will:
- Use a web-based digital education and self-management program with multiple e-learning modules tailored to individual needs and preferences
- Access the program via smartphone, tablet, or computer during inpatient rehabilitation or outpatient care
- Discuss questions related to the program content with healthcare professionals during routine rehabilitation sessions or clinic visits
- Complete questionnaires about their experience with the program and their health-related outcomes
Read the detailed description
Fibrotic interstitial lung diseases (FILD) are a group of rare and chronic lung conditions that are often associated with persistent symptoms, reduced quality of life, and limitations in daily activities. People living with FILD frequently report unmet needs regarding disease-specific education and support for self-management. In particular, patients identify a lack of clear, understandable, and patient-centered educational resources as a major gap in current inpatient rehabilitation and outpatient interstitial lung disease (ILD) care.
To address this need, a blended digital education and self-management program was developed for patients with FILD. The program combines web-based e-learning modules with opportunities for discussion and clarification with healthcare professionals during routine inpatient rehabilitation or outpatient clinical care. The digital content addresses core and optional topics related to disease understanding, symptom management, and self-management strategies. Suggested modules are based on individual patient needs and preferences identified through initial questions within the digital platform, while all modules remain accessible to all users.
This study is an exploratory, multicenter, before-after observational cohort study with an embedded feasibility sub-study. Two cohorts are included: a historical control cohort consisting of patients treated before implementation of the digital program, and a feasibility cohort consisting of patients treated after implementation who consent to participate and receive access to the digital education and self-management program. Participants are not randomized, and investigators do not assign patients to intervention or control groups. Exposure to the program is determined by timing of implementation and patient consent.
The primary objective of the feasibility sub-study is to assess intervention feasibility, including acceptability, perceived usefulness, patient satisfaction, and adherence to the digital program. Adherence is assessed by documenting participation in and completion of the educational modules. Semi-structured interviews with patients and healthcare professionals are conducted to explore barriers and facilitators to implementation in inpatient rehabilitation and outpatient care settings.
Secondary objectives address study feasibility for a future larger effectiveness trial. These objectives include evaluating the feasibility of recruiting the targeted number of participants, retaining participants through follow-up assessments, and collecting health-related outcome data with minimal missing data.
Health-related outcomes are collected to explore patients' responsiveness to the digital education and self-management program and to inform the design of a future effectiveness trial. The primary health-related outcome is self-efficacy, assessed at multiple time points using a pulmonary rehabilitation-adapted self-efficacy measure. Secondary health-related outcomes include health-related quality of life, assessed using a disease-specific questionnaire for interstitial lung disease, as well as changes in self-efficacy at earlier follow-up time points.
Additional exploratory outcomes include functional exercise capacity derived from routinely collected clinical data, patient-reported symptoms and health status using visual analog scales, patient-reported respiratory symptoms, psychological well-being, and supplemental oxygen requirements during activity. These outcomes are collected to provide a comprehensive picture of patient experiences and to evaluate the feasibility and relevance of these measures for future studies.
The digital education and self-management program is delivered through a web-based learning management system and can be accessed via smartphone, tablet, or desktop computer. For inpatient rehabilitation patients, access is provided during the rehabilitation stay, with flexible use throughout the program and support from therapists as needed. Topics from the digital program can be discussed during routine therapy sessions, and patients retain access to the digital resources after discharge. For outpatient care patients, access is provided during an ILD clinic visit, with opportunities to discuss program content during follow-up appointments and reminders to encourage engagement.
Overall, this study aims to generate essential information on the feasibility and acceptability of implementing a digital education and self-management program for patients with FILD, while providing preliminary data on relevant health-related outcomes to support planning of a future multicenter effectiveness trial.
- Conditions
- Lung Fibrosis Interstitial
- Being tested
- Blended patient education and self-management programme
- Keywords
- self-management, patient education, self-efficacy, blended learning, lung fibrosis, ILD, digital patient information
- Medical subject headings
- Pulmonary Fibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blended patient education and self-management programmeBehavioural
The program consists of multiple web-based e-learning modules covering core and optional topics relevant to lung fibrosis. Modules are suggested based on individual symptoms and self-management needs, but all content is accessible to all users. The program can be accessed via smartphone, tablet, or computer using a web link. It is intended solely for education and well-being support and is not used for diagnosis, monitoring, treatment, or prognosis of disease.
In inpatient rehabilitation, patients may use the program flexibly during their stay, with support from therapists as needed, and can discuss content during routine therapy sessions. In outpatient care, patients receive access during an ILD clinic visit and can discuss content during follow-up appointments, supported by reminders to encourage use.
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Experimental | This arm includes patients with fibrotic interstitial lung diseases enrolled in the observational study during the feasibility phase. Participants who consent to participate are offered access to a blended digital education and self-management program in addition to usual inpatient pulmonary rehabilitation or outpatient ILD care. Receives: Behavioral: Blended patient education and self-management programme |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intervention feasibility outcomes - Acceptance
Acceptability of Intervention Measure (AIM): 4-item questioniare measuring the acceptability of an intervention on a 5-likert scale (completely disagree to completely agree).
Measured: 3-6 months follow-up
Intervention feasibility outcomes - Appropriateness
Intervention Appropriateness Measure (IAM): 4-item questioniare measuring the appropriation of an intervention on a 5-likert scale (completely disagree to completely agree).
Measured: 3-6 months follow-up
Intervention feasibility outcomes - Feasibiilty
Feasibility of Intervention Measure (FIM): 4-item questioniare measuring the acceptability of an intervention on a f-likert scale (completely disagree to completely agree).
Measured: 3-6 months follow-up
Intervention feasibility outcomes - Compliance
percent of attended/performed educational modules.
Measured: 3-6 months follow-up
Intervention feasibility outcomes - Farriers and facilitators
Consecutive semi-structured patient and staff interviews will be performed until data saturation to explore barriers and facilitators for implementation.
Measured: 3-6 months follow-up
Secondary outcomes (11)
Study feasibility outcomes - Recruitment success
Recruitment success: Time to assess the targeted the 50 patients for the feasibility study.
Measured: 3-6 months
Study feasibility outcomes - Retention
Number of recruited patients that successfully completed the study (pre- and post-assessment)
Measured: 3-6 months
Study feasibility outcomes - Data collection:
Percentage of missing data in outcome assessments.
Measured: 3-6 months
Health related outcomes - self efficacy
Change in self-efficacy from t0 to t1 and t2, assessed with the Pulmonary Rehabilitation Adapted Index of Self-Efficacy
Measured: 3- 6 months follow-up
Health related outcomes - HRQoL
Change in HRQOL from t0 to t1 and t2 assessed by the King's Brief Interstitial Lung Disease health status questionnaire
Measured: 3- 6 months follow-up
Health related outcomes - functional status
functional status assessed by six-minute walking test (routinely collected data)
Measured: from start to end of inpatient rehabilitation
Health related outcomes - self-reported health status (VAS)
Measured: 3- 6 months follow-up
Health related outcomes - Anxiety and Depression Score
Self-reported anxiety and depression (Hospital Anxiety and Depression Scale)
Measured: 3- 6 months follow-up
Health related outcomes - oxygen supplementation
Supplemental oxygen needs for activity and at rest (routinely collected data)
Measured: 3- 6 months follow-up
Health related outcomes - Re-hospitalization
re-hospitalization (y/n)
Measured: 3- 6 months follow-up
Health related outcomes - survival
survival (y/n)
Measured: 3- 6 months follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Mar 2026
- Study start7 Oct 2025
- Primary completionAug 2027 (estimated)
- Study completionAug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Fibrosis InterstitialStudies of the same condition, open and under way.
- More trials run by Insel Gruppe AG, University Hospital BernThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This study uses a single-group, before-after observational design. All participants enrolled after implementation who consent to participate are offered access to the same digital education and self-management program. There is no randomization and no prospective assignment of participants to different interventions. Outcomes are assessed over time within the same group and compared with data from a historical cohort of patients treated prior to implementation of the program.
- Masking
- None (open label)
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Sponsor type
- University, hospital or other
- Collaborators
- University of Zurich, ZHAW School of Health Professions, Institute of Physiotherapy
- Responsible party
- Sponsor
- Investigators
- Thimo Marcin, PHD, Principal investigator, Center for Rehabilitation & Sports Medicine Inselspital and Berner Reha Zentrum, Bern University Hospital, University of Bern, SwitzerlandSabina Guler, MD, Principal investigator, Department for Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07457463
- Sponsor's protocol ID
- 2023-01318
- Other IDs
- 2023
- Acronym
- FILIP
- Status last verified
- Mar 2026
- First submitted
- 20 Jan 2026
- Last updated
- 9 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual patient data for patients who signed the additional informed consent for further use of data may be shared upon request.
Study at a glance
From the registry record, last updated by the sponsor on 9 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Self-efficacy and Well-being of Patients With Fibrotic Interstitial Lung Disease - an Observational Study
- ClinicalTrials.gov ID
- NCT07457463
- Acronym / sponsor ID
- FILIP / 2023-01318
- Conditions
- Lung Fibrosis Interstitial
- Keywords
- self-management, patient education, self-efficacy, blended learning, lung fibrosis, ILD, digital patient information
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Insel Gruppe AG, University Hospital BernUniversity, hospital or other
- Collaborators
- University of Zurich, ZHAW School of Health Professions, Institute of Physiotherapy
- Study start
- 7 Oct 2025 (actual)
- Primary completion
- Aug 2027 (estimated)
- Study completion
- Aug 2027 (estimated)
- First posted
- 9 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to evaluate the feasibility and acceptability of a newly developed digital education and self-management program for people with fibrotic interstitial lung diseases (FILD) during inpatient pulmonary rehabilitation and outpatient interstitial lung disease (ILD) care. The study also explores whether participation in the program is associated with changes in health-related outcomes.
The main questions this study aims to answer are:
- Is the digital education and self-management program acceptable, useful, and practical for patients with FILD?
- Is it feasible to recruit and retain patients and to collect outcome data for a future larger effectiveness study?
- Do patients who participate in the program show differences in health-related outcomes compared with patients treated before the program was implemented?
Patients who consent to participate during the implementation phase will be offered access to the digital education and self-management program. Their outcomes will be compared with those of a historical cohort of patients who received usual care before the program was introduced.
Participants will:
- Use a web-based digital education and self-management program with multiple e-learning modules tailored to individual needs and preferences
- Access the program via smartphone, tablet, or computer during inpatient rehabilitation or outpatient care
- Discuss questions related to the program content with healthcare professionals during routine rehabilitation sessions or clinic visits
- Complete questionnaires about their experience with the program and their health-related outcomes
Detailed description
Fibrotic interstitial lung diseases (FILD) are a group of rare and chronic lung conditions that are often associated with persistent symptoms, reduced quality of life, and limitations in daily activities. People living with FILD frequently report unmet needs regarding disease-specific education and support for self-management. In particular, patients identify a lack of clear, understandable, and patient-centered educational resources as a major gap in current inpatient rehabilitation and outpatient interstitial lung disease (ILD) care.
To address this need, a blended digital education and self-management program was developed for patients with FILD. The program combines web-based e-learning modules with opportunities for discussion and clarification with healthcare professionals during routine inpatient rehabilitation or outpatient clinical care. The digital content addresses core and optional topics related to disease understanding, symptom management, and self-management strategies. Suggested modules are based on individual patient needs and preferences identified through initial questions within the digital platform, while all modules remain accessible to all users.
This study is an exploratory, multicenter, before-after observational cohort study with an embedded feasibility sub-study. Two cohorts are included: a historical control cohort consisting of patients treated before implementation of the digital program, and a feasibility cohort consisting of patients treated after implementation who consent to participate and receive access to the digital education and self-management program. Participants are not randomized, and investigators do not assign patients to intervention or control groups. Exposure to the program is determined by timing of implementation and patient consent.
The primary objective of the feasibility sub-study is to assess intervention feasibility, including acceptability, perceived usefulness, patient satisfaction, and adherence to the digital program. Adherence is assessed by documenting participation in and completion of the educational modules. Semi-structured interviews with patients and healthcare professionals are conducted to explore barriers and facilitators to implementation in inpatient rehabilitation and outpatient care settings.
Secondary objectives address study feasibility for a future larger effectiveness trial. These objectives include evaluating the feasibility of recruiting the targeted number of participants, retaining participants through follow-up assessments, and collecting health-related outcome data with minimal missing data.
Health-related outcomes are collected to explore patients' responsiveness to the digital education and self-management program and to inform the design of a future effectiveness trial. The primary health-related outcome is self-efficacy, assessed at multiple time points using a pulmonary rehabilitation-adapted self-efficacy measure. Secondary health-related outcomes include health-related quality of life, assessed using a disease-specific questionnaire for interstitial lung disease, as well as changes in self-efficacy at earlier follow-up time points.
Additional exploratory outcomes include functional exercise capacity derived from routinely collected clinical data, patient-reported symptoms and health status using visual analog scales, patient-reported respiratory symptoms, psychological well-being, and supplemental oxygen requirements during activity. These outcomes are collected to provide a comprehensive picture of patient experiences and to evaluate the feasibility and relevance of these measures for future studies.
The digital education and self-management program is delivered through a web-based learning management system and can be accessed via smartphone, tablet, or desktop computer. For inpatient rehabilitation patients, access is provided during the rehabilitation stay, with flexible use throughout the program and support from therapists as needed. Topics from the digital program can be discussed during routine therapy sessions, and patients retain access to the digital resources after discharge. For outpatient care patients, access is provided during an ILD clinic visit, with opportunities to discuss program content during follow-up appointments and reminders to encourage engagement.
Overall, this study aims to generate essential information on the feasibility and acceptability of implementing a digital education and self-management program for patients with FILD, while providing preliminary data on relevant health-related outcomes to support planning of a future multicenter effectiveness trial.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This study uses a single-group, before-after observational design. All participants enrolled after implementation who consent to participate are offered access to the same digital education and self-management program. There is no randomization and no prospective assignment of participants to different interventions. Outcomes are assessed over time within the same group and compared with data from a historical cohort of patients treated prior to implementation of the program.
| Arm | Type | Receives |
|---|---|---|
| Intervention group | Experimental | Behavioral: Blended patient education and self-management programmeThis arm includes patients with fibrotic interstitial lung diseases enrolled in the observational study during the feasibility phase. Participants who consent to participate are offered access to a blended digital education and self-management program in addition to usual inpatient pulmonary rehabilitation or outpatient ILD care. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Diagnosis of a FILD as major indication for pulmonary rehabilitation (for Berner Reha Zentrum only)
- Enrolled in Idiopathic interstitial Pneumonia (IIP) cohort study (Nr. 246/15 / PB_2016-01524) and agreed to further use of data for further research purpose (for Inselspital only)
- Age ≥ 18 years
- Written informed consent
Key exclusion criteria (2 listed)
- Cognitive inability or insufficient knowledge of project language (German) to follow informed consent or study procedures
- Sarcoidosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blended patient education and self-management programmeThe program consists of multiple web-based e-learning modules covering core and optional topics relevant to lung fibrosis. Modules are suggested based on individual symptoms and self-management needs, but all content is accessible to all users. The program can be accessed via smartphone, tablet, or computer using a web link. It is intended solely for education and well-being support and is not used for diagnosis, monitoring, treatment, or prognosis of disease. In inpatient rehabilitation, patients may use the program flexibly during their stay, with support from therapists as needed, and can discuss content during routine therapy sessions. In outpatient care, patients receive access during an ILD clinic visit and can discuss content during follow-up appointments, supported by reminders to encourage use. | Behavioural | Intervention group |
Primary outcome
Intervention feasibility outcomes - Acceptance
Time frame: 3-6 months follow-up
Acceptability of Intervention Measure (AIM): 4-item questioniare measuring the acceptability of an intervention on a 5-likert scale (completely disagree to completely agree).
Intervention feasibility outcomes - Appropriateness
Time frame: 3-6 months follow-up
Intervention Appropriateness Measure (IAM): 4-item questioniare measuring the appropriation of an intervention on a 5-likert scale (completely disagree to completely agree).
Intervention feasibility outcomes - Feasibiilty
Time frame: 3-6 months follow-up
Feasibility of Intervention Measure (FIM): 4-item questioniare measuring the acceptability of an intervention on a f-likert scale (completely disagree to completely agree).
Intervention feasibility outcomes - Compliance
Time frame: 3-6 months follow-up
percent of attended/performed educational modules.
Intervention feasibility outcomes - Farriers and facilitators
Time frame: 3-6 months follow-up
Consecutive semi-structured patient and staff interviews will be performed until data saturation to explore barriers and facilitators for implementation.
11 secondary outcomes
Study feasibility outcomes - Recruitment success
Time frame: 3-6 months
Study feasibility outcomes - Retention
Time frame: 3-6 months
Study feasibility outcomes - Data collection:
Time frame: 3-6 months
Health related outcomes - self efficacy
Time frame: 3- 6 months follow-up
Health related outcomes - HRQoL
Time frame: 3- 6 months follow-up
Health related outcomes - functional status
Time frame: from start to end of inpatient rehabilitation
Health related outcomes - self-reported health status (VAS)
Time frame: 3- 6 months follow-up
Health related outcomes - Anxiety and Depression Score
Time frame: 3- 6 months follow-up
Health related outcomes - oxygen supplementation
Time frame: 3- 6 months follow-up
Health related outcomes - Re-hospitalization
Time frame: 3- 6 months follow-up
Health related outcomes - survival
Time frame: 3- 6 months follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Mar 2026.
- Individual participant dataSharing planned: Yes. Individual patient data for patients who signed the additional informed consent for further use of data may be shared upon request.
Related trials for Lung Fibrosis Interstitial
RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
RecruitingObservational study
Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome
Hermansky-Pudlak Syndrome (HPS)
RecruitingPhase 2
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Thimo Marcin, PHD principal investigator
Center for Rehabilitation & Sports Medicine Inselspital and Berner Reha Zentrum, Bern University Hospital, University of Bern, Switzerland
Sabina Guler, MD principal investigator
Department for Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blended patient education and self-management programme in people with Lung Fibrosis Interstitial, run by Insel Gruppe AG, University Hospital Bern at 2 sites in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Thimo Marcin, PhD (+41 33 244 3048, thimo.marcin@rehabern.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intervention feasibility outcomes - Acceptance (time frame: 3-6 months follow-up). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2026.